Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 3/2011

01.12.2011 | Review

Liver involvement in subjects with rheumatic disease

verfasst von: Carlo Selmi, Maria De Santis, M Eric Gershwin

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The liver is often overlooked as a target organ, with pathology either secondary to an underlying disease or due to the toxicity of therapies and the medical complications of extrahepatic diseases. It is thus important for the clinical rheumatologist to be aware of the diagnostic procedure to monitor liver injury. Indeed, systemic rheumatologic diseases may be associated with liver abnormalities secondary to the presence of a coexisting autoimmune liver disease (particularly primary biliary cirrhosis or autoimmune hepatitis), the direct involvement of the liver parenchyma, or the impact of medical treatments (particularly methotrexate) on the liver. In addition, the rheumatologist should be aware of the impact of immunosuppressive agents on underlying viral infections, particularly viral hepatitis. We review herein the data on the role of the liver in the clinical management of systemic rheumatic diseases.
Literatur
1.
Selmi C, Mackay IR, Gershwin ME: The immunological milieu of the liver. Semin Liver Dis. 2007, 27: 129-139. 10.1055/s-2007-979466.CrossRefPubMed
2.
Zhou P, Wirthlin L, McGee J, Annett G, Nolta J: Contribution of human hematopoietic stem cells to liver repair. Semin Immunopathol. 2009, 31: 411-419. 10.1007/s00281-009-0166-3.CrossRefPubMed
3.
Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA, Gershwin ME: Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun. 2009, 32: 246-253. 10.1016/j.jaut.2009.02.022.CrossRefPubMed
4.
Tiegs G, Lohse AW: Immune tolerance: what is unique about the liver. J Autoimmun. 2010, 34: 1-6. 10.1016/j.jaut.2009.08.008.CrossRefPubMed
5.
Invernizzi P: Geoepidemiology of autoimmune liver diseases. J Autoimmun. 2010, 34: J300-J306. 10.1016/j.jaut.2009.12.002.CrossRefPubMed
6.
Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G: Autoimmune hepatitis. Semin Immunopathol. 2009, 31: 421-435. 10.1007/s00281-009-0170-7.CrossRefPubMed
7.
Invernizzi P, Selmi C, Poli F, Frison S, Floreani A, Alvaro D, Almasio P, Rosina F, Marzioni M, Fabris L, Muratori L, Qi L, Seldin MF, Gershwin ME, Podda M, Andreoletti M, Andriulli A, Baldini V, Battezzati PM, Benedetti A, Bernuzzi F, Bianchi FB, Bianchi I, Bignotto M, Bragazzi MC, Brunetto M, Caimi M, Caliari L, Caporaso N, Casella G, et al: Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology. 2008, 48: 1906-1912. 10.1002/hep.22567.CrossRefPubMed
8.
Aron JH, Bowlus CL: The immunobiology of primary sclerosing cholangitis. Semin Immunopathol. 2009, 31: 383-397. 10.1007/s00281-009-0154-7.CrossRefPubMed
9.
Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME: Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis. 2005, 25: 265-280. 10.1055/s-2005-916319.CrossRefPubMed
10.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD: Liver biopsy. Hepatology. 2009, 49: 1017-1044. 10.1002/hep.22742.CrossRefPubMed
11.
Longhi MS, Ma Y, Mieli-Vergani G, Vergani D: Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010, 34: 7-14. 10.1016/j.jaut.2009.08.010.CrossRefPubMed
12.
Hohenester S, Oude-Elferink RP, Beuers U: Primary biliary cirrhosis. Semin Immunopathol. 2009, 31: 283-307. 10.1007/s00281-009-0164-5.CrossRefPubMed
13.
Youssef WI, Tavill AS: Connective tissue diseases and the liver. J Clin Gastroenterol. 2002, 35: 345-349. 10.1097/00004836-200210000-00012.CrossRefPubMed
14.
Abraham S, Begum S, Isenberg D: Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004, 63: 123-129. 10.1136/ard.2002.001826.CrossRefPubMed
15.
Fix OK, Damon LE, Bass NM: Amyloidosis localized to the liver. Clin Gastroenterol Hepatol. 2007, 5: e7-10.1016/j.cgh.2006.11.006.CrossRefPubMed
16.
Runyon BA, LaBrecque DR, Anuras S: The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980, 69: 187-194. 10.1016/0002-9343(80)90378-2.CrossRefPubMed
17.
Matsumoto T, Yoshimine T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, Hoshi T: The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol. 1992, 23: 1151-1158. 10.1016/0046-8177(92)90033-Y.CrossRefPubMed
18.
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG: Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008, 35: 2159-2164. 10.3899/jrheum.080336.CrossRefPubMed
19.
D'Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969, 46: 428-440. 10.1016/0002-9343(69)90044-8.CrossRefPubMed
20.
Tsuneyama K, Harada K, Katayanagi K, Watanabe K, Kurumaya H, Minato H, Nakanuma Y: Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol. 2002, 17: 217-223. 10.1046/j.1440-1746.2002.02587.x.CrossRefPubMed
21.
Kaplan MJ, Ike RW: The liver is a common non-exocrine target in primary Sjogren's syndrome: a retrospective review. BMC Gastroenterol. 2002, 2: 21-10.1186/1471-230X-2-21.CrossRefPubMed
22.
Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, Mikayama T, Van De Water J, Coppel RL, Kaplan M, Gershwin ME: Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 2002, 123: 1031-1043. 10.1053/gast.2002.36020.CrossRefPubMed
23.
Chiorini JA, Cihakova D, Ouellette CE, Caturegli P: Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun. 2009, 33: 190-196. 10.1016/j.jaut.2009.09.009.CrossRefPubMed
24.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J: Behcet's disease - a contemporary review. J Autoimmun. 2009, 32: 178-188. 10.1016/j.jaut.2009.02.011.CrossRefPubMed
25.
von Knorring J, Wassatjerna C: Liver involvement in polymyalgia rheumatica. Scand J Rheumatol. 1976, 5: 197-204. 10.3109/03009747609099905.CrossRefPubMed
26.
Rodriguez-Valverde V, Sarabia JM, Gonzalez-Gay MA, Figueroa M, Armona J, Blanco R, Fernandez-Sueiro JL, Martinez-Taboada VM: Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med. 1997, 102: 331-336. 10.1016/S0002-9343(97)00117-4.CrossRefPubMed
27.
Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, Sato N, Abe H, Aoki Y, Hoshi T, Hashimoto H: The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000, 20: 366-373. 10.1034/j.1600-0676.2000.020005366.x.CrossRefPubMed
28.
Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME: Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol. 1997, 36: 210-213. 10.1093/rheumatology/36.2.210.CrossRefPubMed
29.
Andres E, Locatelli F, Pflumio F, Marcellin L: Liver biopsy is not useful in the diagnosis of adult Still's disease. QJM. 2001, 94: 568-569. 10.1093/qjmed/94.10.568.CrossRefPubMed
30.
Poupon R, Chazouilleres O, Corpechot C, Chretien Y: Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006, 44: 85-90. 10.1002/hep.21229.CrossRefPubMed
31.
Efe C, Ozaslan E, Nasiroglu N, Tunca H, Purnak T, Altiparmak E: The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci. 2010, 55: 2417-2421. 10.1007/s10620-009-0996-9.CrossRefPubMed
32.
Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, Manek N, Perry M, Ganesh D, Rahbar MH, Mayes MD: Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009, 36: 2250-2256. 10.3899/jrheum.090340.CrossRefPubMed
33.
Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T: Clinical, serological and genetic study in patients with CREST syndrome. Intern Med. 2000, 39: 451-456. 10.2169/internalmedicine.39.451.CrossRefPubMed
34.
Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM: Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome. J Rheumatol. 2008, 35: 2012-2016.PubMed
35.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005, 42: 1194-1202. 10.1002/hep.20907.CrossRefPubMed
36.
Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Worns M, Lohse AW, Galle PR, Kanzler S: Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010, 44: 208-213. 10.1097/MCG.0b013e3181c74e0d.CrossRefPubMed
37.
Selmi C, Podda M: Methotrexate for primary biliary cirrhosis: who is to be trusted?. Dig Dis Sci. 2010, 55: 3013-3015. 10.1007/s10620-010-1435-7.CrossRefPubMed
38.
Kaplan MM, Bonder A, Ruthazer R, Bonis PA: Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci. 2010, 55: 3207-3217. 10.1007/s10620-010-1291-5.CrossRefPubMed
39.
Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF: Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005, 42: 1184-1193. 10.1002/hep.20897.CrossRefPubMed
40.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM: Diagnosis and management of autoimmune hepatitis. Hepatology. 2010, 51: 2193-2213. 10.1002/hep.23584.CrossRefPubMed
41.
Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, Ma Y: Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008, 47: 581-591. 10.1002/hep.22071.CrossRefPubMed
42.
Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E: Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011, 54: 374-385. 10.1016/j.jhep.2010.09.002.CrossRefPubMed
43.
Coffin CS, Fraser HF, Panaccione R, Ghosh S: Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011, 17: 479-484. 10.1002/ibd.21336.CrossRefPubMed
44.
Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Gorla R: Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev. 2009, 8: 260-265. 10.1016/j.autrev.2008.11.001.CrossRefPubMed
45.
Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A: Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009, 8: 266-273. 10.1016/j.autrev.2008.11.002.CrossRefPubMed
46.
Deane S, Meyers FJ, Gershwin ME: On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. J Autoimmun. 2008, 30: 180-196. 10.1016/j.jaut.2007.12.001.CrossRefPubMed
47.
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE, American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008, 59: 762-784. 10.1002/art.23721.CrossRefPubMed
48.
Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology. 2009, 50: 661-662. 10.1002/hep.23190.CrossRefPubMed
49.
Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49: 1335-1374. 10.1002/hep.22759.CrossRefPubMed
50.
Hou JK, Velayos F, Terrault N, Mahadevan U: Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010, 16: 925-932.CrossRefPubMed
51.
Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokhar F, Lutchman G, Kleiner DE, Young NS, Childs R, Barrett AJ, Liang TJ, Hoofnagle JH, Heller T: Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009, 7: 1130-1137. 10.1016/j.cgh.2009.06.027.CrossRefPubMed
52.
Davern TJ, Chalasani N: Drug-induced liver injury in clinical trials: as rare as hens' teeth. Am J Gastroenterol. 2009, 104: 1159-1161. 10.1038/ajg.2009.76.CrossRefPubMed
53.
Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B: The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study. Aliment Pharmacol Ther. 2010, 32: 478-486. 10.1111/j.1365-2036.2010.04364.x.CrossRefPubMed
54.
Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA: Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010, 9: 188-193. 10.1016/j.autrev.2009.10.003.CrossRefPubMed
55.
Quintin E, Scoazec JY, Marotte H, Miossec P: Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010, 12: R143-10.1186/ar3085.CrossRefPubMed
56.
Raimondo G, Pollicino T, Cacciola I, Squadrito G: Occult hepatitis B virus infection. J Hepatol. 2007, 46: 160-170. 10.1016/j.jhep.2006.10.007.CrossRefPubMed
57.
Jansen TL: When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?. Arthritis Res Ther. 2010, 12: 103-10.1186/ar2899.CrossRefPubMed
58.
Calabrese LH, Zein NN, Vassilopoulos D: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006, 65: 983-989. 10.1136/ard.2005.043257.CrossRefPubMed
59.
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J: Consideration of strategies for hematopoietic cell transplantation. J Autoimmun. 2009, 33: 255-259. 10.1016/j.jaut.2009.09.002.CrossRefPubMed
60.
Kushida T, Ueda Y, Umeda M, Oe K, Okamoto N, Iida H, Abraham NG, Gershwin ME, Ikehara S: Allogeneic intra-bone marrow transplantation prevents rheumatoid arthritis in SKG/Jcl mice. J Autoimmun. 2009, 32: 216-222. 10.1016/j.jaut.2009.02.015.CrossRefPubMed
61.
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P: Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009, 4: CD007848-PubMed
62.
Nurmohamed MT: Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?. Drugs. 2009, 69: 2035-2043. 10.2165/11318290-000000000-00000.CrossRefPubMed
Metadaten
Titel
Liver involvement in subjects with rheumatic disease
verfasst von
Carlo Selmi
Maria De Santis
M Eric Gershwin
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 3/2011
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3319

Weitere Artikel der Ausgabe 3/2011

Arthritis Research & Therapy 3/2011 Zur Ausgabe

Research article

CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes

Research article

Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines

Research article

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity

Commentary

Biosimilars: a regulatory perspective from America

Research article

Defective response of CD4+ T cells to retinoic acid and TGFβ in systemic lupus erythematosus

Research article

The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise